<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2005-9-4-41-45</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-719</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>ЗНАЧЕНИЕ АННЕКСИНА¬5 В ОЦЕНКЕ ТЯЖЕСТИ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ НА ДОКЛИНИЧЕСКОЙ СТАДИИ АТЕРОСКЛЕРОЗА У БОЛЬНЫХ ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК</article-title><trans-title-group xml:lang="en"><trans-title>SIGNIFICANCE OF ANNEXIN¬5 IN EVALUATION OF THE DEGREE OF ENDOTHELIAL DYSFUNCTION AT THE PRECLINICAL STAGE OF ATHEROSCLEROSIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панина</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Panina</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрищев</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrishcyhev</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добронравов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobronravov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меншутина</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Menshutina</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тугушева</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tugusheva</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дегтерева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Degtereva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>А. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>A. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трофименко</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Trofimenko</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаранина</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Garanina</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патофизиологии и кафедра пропедевтики внутренних болезней</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>10</day><month>04</month><year>2005</year></pub-date><volume>9</volume><issue>4</issue><fpage>41</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Смирнов А.В., Панина И.Ю., Петрищев Н.Н., Добронравов В.А., Меншутина М.А., Тугушева Ф.А., Дегтерева О.А., Румянцев А.Ш., Трофименко И.И., Гаранина А.Е., 2005</copyright-statement><copyright-year>2005</copyright-year><copyright-holder xml:lang="ru">Смирнов А.В., Панина И.Ю., Петрищев Н.Н., Добронравов В.А., Меншутина М.А., Тугушева Ф.А., Дегтерева О.А., Румянцев А.Ш., Трофименко И.И., Гаранина А.Е.</copyright-holder><copyright-holder xml:lang="en">Smirnov A.V., Panina I.Y., Petrishcyhev N.N., Dobronravov V.A., Menshutina M.A., Tugusheva F.A., Degtereva O.A., Rumyantsev A.S., Trofimenko I.I., Garanina A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/719">https://journal.nephrolog.ru/jour/article/view/719</self-uri><abstract><p>ЦЕЛЬ ИССЛЕДОВАНИЯ. Оценить значение аннексина5 (Ан5) на доклинической стадии атеросклероза у больных хронической болезнью почек. ПАЦИЕНТЫ И МЕТОДЫ. Обследовали 46 больных ХБП без клинической симптоматики атеросклероза. Определяли показатели липидограммы, комплекс интимамедиа сонной артерии, реактивность сосудов микроциркуляторного русла, уровень Ан5. РЕЗУЛЬТАТЫ. Снижение скорости клубочковой фильтрации сопровождается нарастанием уровня Ан5. Его концентрация взаимосвязана с показателями липидограммы. Повышение уровня аннекси на5 сопровождается наиболее выраженной дисфункцией эндотелия. ЗАКЛЮЧЕНИЕ. Повышение уровня Ан5 в крови больных ХБП особенно информативно при отсутствии клинической симптоматики атеросклероза и свидетельствует о наличии вазомоторной формы эндотелиальной дисфункции, Динамическое определение концентрации Ан5 может улучшить прогностическую оценку вероятности наступления сердечнососудистых катастроф при заболеваниях почек.</p></abstract><trans-abstract xml:lang="en"><p>THE AIM of the investigation was to assess the significance of annexin5 (An5) at the preclinical stage of atherosclerosis in patients with chronic kidney disease. PATIENTS AND METHODS. Under investigation there were 46 patients with CKD without clinical manifestations of atherosclerosis. The parameters of lipidogram, complex intimamedia thickness, endothelial dysfunction and the An5 level were determined. RESULTS. The decreased GFR was followed by an increased An5 level. Its concentration was interconnected with the lipidogram indices. The increased level of annexin5 is accompanied by the most pronounced dysfunction of the endothelium. CONCLUSION. The elevated level of An5 in CKD patients’ blood is especially informative with the absence of clinical symptoms of atherosclerosis and points to the vasomotor form of endothelial dysfunction. The dynamic detection of An 5 can improve the prognostic value of probable cardiovascular problems in patients with CKD.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>атеросклероз</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>аннексин5</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic renal disease</kwd><kwd>atherosclerosis</kwd><kwd>endothelial dysfunction</kwd><kwd>annexin5</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Collins AJ, Li Sh, Gilbertson D et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003; 64 [suppl 87]: 2431</mixed-citation><mixed-citation xml:lang="en">Collins AJ, Li Sh, Gilbertson D et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003; 64 [suppl 87]: 2431</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rabelink TJ. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? Nephrol Dial Transplant 2004; 19: 2326</mixed-citation><mixed-citation xml:lang="en">Rabelink TJ. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? Nephrol Dial Transplant 2004; 19: 2326</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, risk factors and impact urbanization. Circulation 2001; 104: 2746 2653</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, risk factors and impact urbanization. Circulation 2001; 104: 2746 2653</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher SA, Langille BL, Srivastava D. Apoptosis during cardiovascular development. Circ Res 2000; 87: 856864</mixed-citation><mixed-citation xml:lang="en">Fisher SA, Langille BL, Srivastava D. Apoptosis during cardiovascular development. Circ Res 2000; 87: 856864</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gerke V, Moss ES. Annexins: From Structure to Function. Physiol Rev 2002; 82: 331–371</mixed-citation><mixed-citation xml:lang="en">Gerke V, Moss ES. Annexins: From Structure to Function. Physiol Rev 2002; 82: 331–371</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hawkins TE, Das D, Young B, Moss SE. DT40 cells lacking the Ca2binding protein annexin5 are resistant to Ca2 dependent apoptosis. Proc Natl Acad Sci 2002; 99: 8054–8059</mixed-citation><mixed-citation xml:lang="en">Hawkins TE, Das D, Young B, Moss SE. DT40 cells lacking the Ca2binding protein annexin5 are resistant to Ca2 dependent apoptosis. Proc Natl Acad Sci 2002; 99: 8054–8059</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fadok VA, Bratton DL, Warner ML, Henson PM. The role of phosphatidiylserine in recognition of apoptotic cells by phagocytes. Cell Death Dyjer 1998; 5: 551562</mixed-citation><mixed-citation xml:lang="en">Fadok VA, Bratton DL, Warner ML, Henson PM. The role of phosphatidiylserine in recognition of apoptotic cells by phagocytes. Cell Death Dyjer 1998; 5: 551562</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bombeli T, Karsan A, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429 2442</mixed-citation><mixed-citation xml:lang="en">Bombeli T, Karsan A, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429 2442</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and Tcells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996; 149 (2): 367380</mixed-citation><mixed-citation xml:lang="en">Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and Tcells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996; 149 (2): 367380</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gerke V, Moss ES. Annexins: From Structure to Function. Physiol Rev 2002; 82: 331–371</mixed-citation><mixed-citation xml:lang="en">Gerke V, Moss ES. Annexins: From Structure to Function. Physiol Rev 2002; 82: 331–371</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dayer E, Blanc E, Wauters JPE. Dayer early T cell activation correlates with expression of apoptosis markers in patients with endstage renal disease. Am Soc Nephrol 2002; 13(1): 20412</mixed-citation><mixed-citation xml:lang="en">Dayer E, Blanc E, Wauters JPE. Dayer early T cell activation correlates with expression of apoptosis markers in patients with endstage renal disease. Am Soc Nephrol 2002; 13(1): 20412</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">MartinMalo A, Carracedo J, Ramirez R, Rodriguez BenoDayer Et A, Soprano S, Rodriguez M, Aljama P. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000; 11(5): 93642</mixed-citation><mixed-citation xml:lang="en">MartinMalo A, Carracedo J, Ramirez R, Rodriguez BenoDayer Et A, Soprano S, Rodriguez M, Aljama P. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000; 11(5): 93642</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Петрищев НН, Меншутина МА, Власов ТД и др. Па тент на полезную модель №4720. Приоритет полезной модели от 12.04.2005</mixed-citation><mixed-citation xml:lang="en">Петрищев НН, Меншутина МА, Власов ТД и др. Па тент на полезную модель №4720. Приоритет полезной модели от 12.04.2005</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">von Eckardstein A. Is there a need novel cardiovascular risk factors? Nephrol Dial Transplant 2004; 19: 761765</mixed-citation><mixed-citation xml:lang="en">von Eckardstein A. Is there a need novel cardiovascular risk factors? Nephrol Dial Transplant 2004; 19: 761765</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hense HW, Schulte H, Lowel H et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany results from the MONICA Augsburg and Procam cohorts. Eur Heart J 2003; 31: 937345</mixed-citation><mixed-citation xml:lang="en">Hense HW, Schulte H, Lowel H et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany results from the MONICA Augsburg and Procam cohorts. Eur Heart J 2003; 31: 937345</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The Role of oxidant stress. Circ Res 2000; 87: 840844</mixed-citation><mixed-citation xml:lang="en">Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The Role of oxidant stress. Circ Res 2000; 87: 840844</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Васина АВ. Маркеры апоптоза и дисфункция эндо телия при остром коронарном синдроме. Регионарное кровообращение и микроциркуляция 2004; 3 (12): 510</mixed-citation><mixed-citation xml:lang="en">Васина АВ. Маркеры апоптоза и дисфункция эндо телия при остром коронарном синдроме. Регионарное кровообращение и микроциркуляция 2004; 3 (12): 510</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ребров АП, Зелепукина НЮ. Дисфункция эндотелия у больных хроническим гломерулонефритом в различных стадиях почечной недостаточности. Нефрология и диализ 2001; 3 (4): 39 – 46</mixed-citation><mixed-citation xml:lang="en">Ребров АП, Зелепукина НЮ. Дисфункция эндотелия у больных хроническим гломерулонефритом в различных стадиях почечной недостаточности. Нефрология и диализ 2001; 3 (4): 39 – 46</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Watts GF, Herrmann S, Dogra GK et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60 (1): 182 – 187</mixed-citation><mixed-citation xml:lang="en">Watts GF, Herrmann S, Dogra GK et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60 (1): 182 – 187</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Paisley KE, Beaman M, Tooke JE et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63 (2): 624 – 631</mixed-citation><mixed-citation xml:lang="en">Paisley KE, Beaman M, Tooke JE et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63 (2): 624 – 631</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
